Ribeiro DC, Gleber-Netto
FO, Sousa SF, Bernardes VF, Guimarães-Abreu MHN, Aguiar MCF. Immunohistochemical expression of EGFR in oral leukoplakia: Association with clinicopathological
features and cellular proliferation. Med Oral Patol Oral Cir Bucal. 2012 Sep 1;17 (5):e739-44.
doi:10.4317/medoral.17950
http://dx.doi.org/doi:10.4317/medoral.17950
1. Warnakulasuriya S,
Johnson NW, van der Waal I. Nomenclature and
classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80.
http://dx.doi.org/10.1111/j.1600-0714.2007.00582.x
2. van der
Waal I. Potentially malignant disorders of the oral and oropharyngeal
mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317-23.
http://dx.doi.org/10.1016/j.oraloncology.2008.05.016
PMid:18674954
3. Warnakulasuriya S, Reibel
J, Bouquot J, Dabelsteen E.
Oral epithelial dysplasia classification systems: predictive value, utility,
weaknesses and scope for improvement. J Oral Pathol
Med. 2008;37:127-33.
http://dx.doi.org/10.1111/j.1600-0714.2007.00584.x
4. Dietrich T, Reichart
PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US
population. Oral Oncol.
2004;40:158-63.
http://dx.doi.org/10.1016/S1368-8375(03)00145-3
5. Gümüş ZH, Du B, Kacker A, Boyle JO, Bocker JM, Mukherjee P, et al. Effects of tobacco smoke on gene
expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev
Res (Phila). 2008;1:100-11.
http://dx.doi.org/10.1158/1940-6207.CAPR-08-0007
PMid:19138943
6. Zhang L, Cheung KJ Jr, Lam WL, Cheng X, Poh C, Priddy R, et al. Increased
genetic damage in oral leukoplakia from high risk
sites: potential impact on staging and clinical management. Cancer.
2001;91:2148-55.
http://dx.doi.org/10.1002/1097-0142(20010601)91:11<2148::AID-CNCR1243>3.0.CO;2-G
7. Pitiyage G, Tilakaratne
WM, Tavassoli M, Warnakulasuriya
S. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med. 2009;38:737-52.
http://dx.doi.org/10.1111/j.1600-0714.2009.00804.x
8. O-charoenrat P, Rhys-Evans
PH, Modjtahedi H, Eccles SA. The
role of c-erbB receptors and ligands
in head and neck squamous cell carcinoma. Oral Oncol. 2002;38:627-40.
PMid:12167415
9. Sarkis SA, Abdullah BH, Abdul Majeed
BA, Talabani NG. Immunohistochemical expression of
epidermal growth factor receptor (EGFR) in oral squamous
cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol.
2010;2:13.
http://dx.doi.org/10.1186/1758-3284-2-13
10. Tsantoulis PK, Kastrinakis NG, Tourvas
AD, Laskaris G, Gorgoulis
VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43:523-34.
http://dx.doi.org/10.1016/j.oraloncology.2006.11.010
PMid:17258495
11. Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura
P, González-López T, Castro-Santana MD, López-Mola E, et al. Epidermal growth factor in clinical practice - a
review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6:331-46.
http://dx.doi.org/10.1111/j.1742-481X.2009.00622.x
PMid:19912390
12. Benchekroun MT, Saintigny
P, Thomas SM, El-Naggar AK, Papadimitrakopoulou
V, Ren H, et al. Epidermal growth factor receptor
expression and gene copy number in the risk of oral cancer. Cancer Prev Res. 2010;3:800-9.
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0163
PMid:20570883 PMCid:2900459
13. Grandis JR, Tweardy DJ,
Melhem MF. Asynchronous modulation
of transforming growth factor alpha and epidermal growth factor receptor
protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin
Cancer Res. 1998;4:13-20.
PMid:9516947
14. Nagatsuka H, Ishiwari
Y, Tsujigiwa H, Nakano K, Nagai N. Quantitation of epidermal growth factor receptor gene
amplification by competitive polymerase chain reaction in pre-malignant and
malignant oral epithelial lesions. Oral Oncol.
2001;37:599-604.
http://dx.doi.org/10.1016/S1368-8375(01)00051-3
15. Shin DM, Ro JY, Hong WK, Hittelman
WN. Dysregulation of epidermal growth factor receptor expression in premalignant
lesions during head and neck tumorigenesis.
Cancer Res. 1994;54:3153-59.
PMid:8205534
16. Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM. ErbB receptor tyrosine kinases
contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res. 2009;19:156-166.
http://dx.doi.org/10.1097/CMR.0b013e32832c6339
PMid:19434003
17. Lee EJ, Whang JH, Jeon
NK, Kim J. The epidermal growth factor receptor tyrosine kinase
inhibitor ZD1839 (Iressa) suppresses proliferation
and invasion of human oral squamous carcinoma cells
via p53 independent and MMP, uPAR dependent
mechanism. Ann N Y Acad Sci. 2007;1095:113-128.
http://dx.doi.org/10.1196/annals.1397.015
PMid:17404024
18. Shintani S, Li C, Mihara
M, Yano J, Terakado N, Nakashiro
K, et al. Gefitinib (‘Iressa’,
ZD1839), an epidermal growth factor receptor tyrosine kinase
inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 2004;40:43-51.
http://dx.doi.org/10.1016/S1368-8375(03)00131-3
19. Diniz-Freitas M,
Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic
evaluation of EGFR expression in oral squamous cell
carcinoma. Oral Dis. 2007;13:285-90.
http://dx.doi.org/10.1111/j.1601-0825.2006.01280.x
PMid:17448210
20. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla
A, Martinez-Lara I. Suprabasal expression of Ki-67
antigen as a marker for the presence and severity of oral epithelial dysplasia.
Head Neck. 2000;22:658-61.
http://dx.doi.org/10.1002/1097-0347(200010)22:7<658::AID-HED3>3.0.CO;2-A
21. Kovesi G, Szende B.
Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia. J Oral Pathol Med.
2006;35:274-77.
http://dx.doi.org/10.1111/j.1600-0714.2006.00396.x
PMid:16630290
22. Srinivasan M, Jewell SD. Evaluation of TGF-alpha
and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry.
Oncology. 2001;61:284-92.
http://dx.doi.org/10.1159/000055335
PMid:11721175
23. Rautava J, Jee KJ, Miettinen PJ, Nagy B, Myllykangas
S, Odell EW, et al. ERBB receptors in developing, dysplastic and malignant oral
epithelia. Oral Oncol. 2008;44:227-35.
http://dx.doi.org/10.1016/j.oraloncology.2007.02.012
PMid:17604679
24. Kan JU, Koo SH, Kwon KC, Park JW, Jung SS. Gain of the EGFR gene located on
7p12 is a frequent and early event in squamous cell
carcinoma of the lung. Cancer Genet
Cytogenet. 2008;184:31-7.
http://dx.doi.org/10.1016/j.cancergencyto.2008.03.002
PMid:18558286
25. Du B, Altork NK, Kopelovich L, Subbaramaiah K, Dannenberg
AJ. Tobacco smoke stimulates the transcription of amphiregulin
in human oral epithelial cells: evidence of a cyclic AMP-responsive element
binding protein-dependent mechanism. Cancer Res. 2005;65:5982-88.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0628
PMid:15994978
26. Du B, Leung H, Khan KM, Miller CG, Subbaramaiah
K, Falcone DJ, et al. Tobacco smoke induces urokinase-type plasminogen
activator and cell invasiveness: evidence for an epidermal growth factor
receptor dependent mechanism. Cancer Res. 2007;67:8966-72.
http://dx.doi.org/10.1158/0008-5472.CAN-07-1388
PMid:17875740
27. Liu SC, Klein-Szanto AJ.
Markers of proliferation in normal and leukoplakic
oral epithelia. Oral Oncol.
2000;36:145-51.
http://dx.doi.org/10.1016/S1368-8375(99)00076-7
28. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I. Immunohistological evaluation of Ki-67, p63, CK19 and p53
expression in oral epithelial dysplasias. J Oral Pathol Med. 2006;35:369-75.
http://dx.doi.org/10.1111/j.1600-0714.2006.00444.x
PMid:16762018
29. Jordan RC, Bradley G, Slingerland J. Reduced
levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and
carcinoma of the oral cavity. Am J Pathol.
1998;152:585-90.
PMid:9466585 PMCid:1857966
30. Tsuzuki H, Fujieda S, Sunaga H, Narita N, Tokuriki M, Saito H. Expression of p27 and apoptosis in
oral leukoplakia. Anticancer Res. 2003;23:1265-70.
PMid:12820381
31. Ben-Izhak O, Kablan F, Laster Z, Nagler
RM. Oropharyngeal cancer pathogenesis: ubiquitin proteolytic, apoptotic
and epidermal growth factor related pathways act in concert-first report. Oral Oncol.
2005;4:851-60.
http://dx.doi.org/10.1016/j.oraloncology.2005.04.012
PMid:16043384